Ignite Creation Date:
2025-12-25 @ 2:40 AM
Ignite Modification Date:
2026-03-01 @ 12:04 PM
Study NCT ID:
NCT01997333
Status:
COMPLETED
Last Update Posted:
2019-03-08
First Post:
2013-11-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Sponsor:
Celldex Therapeutics
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-11
Start Date Type:
None
Primary Completion Date:
2017-11-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-08-07
Completion Date Type:
ACTUAL
First Submit Date:
2013-11-18
First Submit QC Date:
None
Study First Post Date:
2013-11-28
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-11-30
Results First Submit QC Date:
None
Results First Post Date:
2019-03-08
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-03-06
Last Update Post Date:
2019-03-08
Last Update Post Date Type:
ACTUAL